Orphan drug developers face significant difficulties when navigating market access frameworks in Europe. Could greater use of ...

GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033, with Novo Nordisk and Eli Lilly to dominate ...

The FDA has cleared the IND for Ensoma's EN-374, targeting X-linked chronic granulomatous disease (X-CGD), a rare genetic ...

US President Donald Trump has signed an executive order telling drugmakers to cut prices to 'most favoured nation' pricing.

Abeona’s deal value is in line with recent voucher sale transactions amid uncertain times in rare disease drug development.

Mobile healthcare, web-based tech, and wearables are all contributing to a clinical trials landscape that puts the patient ...

The Trump administration has introduced legislation outlining plans for deep cuts to Medicaid, possibly impacting millions of ...

The European Commission (EC) has granted orphan drug designation to Biodexa Pharmaceuticals’ oral tablet formulation of ...

The UK MHRA has approved AstraZeneca's Trixeo Aerosphere inhaler to treat adults with chronic obstructive pulmonary disease ...

AI and machine learning can transform fragmented and unstructured healthcare data. But how do you refine it into useful, ...